Cytovia therapeutics pipeline
WebSep 12, 2024 · Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. WebOct 8, 2024 · NEW YORK, NY, USA and PARIS, France I October 08, 2024 I Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of …
Cytovia therapeutics pipeline
Did you know?
WebCytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline September 13th, 2024 Watch a replay … WebNov 11, 2024 · 18 Apr 2024 Cytovia intends to submit IND application in Solid tumours in 2024 (Cytovia Therapeutics pipeline, April 2024) 17 Mar 2024 CytoImmune Therapeutics plans a phase I trial in Glioblastoma and Solid tumours (Intracerebral) (CytoImmune Therapeutics' pipeline, March 2024) ...
WebMar 17, 2024 · CAMBRIDGE, Mass. and AVENTURA, Fla., March 17, 2024 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric...
WebTherapeutic Area: Oncology Product Name: CYT-303 Highest Development Status: Preclinical Product Type: Cell and Gene therapy Recipient: Cellectis Deal Size: $825.0 million Upfront Cash: $20.0 million Deal Type: Collaboration April 27, 2024 ASK US Upload your Pipeline Activity Cytovia Therapeutics WebSep 13, 2024 · Cytovia and TF Capital, a leading China-based biotech institutional investor, have formed CytoLynx Therapeutics. TF Capital along with YF Capital, BioTrack Capital, Ruihua Capital, and TG Sino-Dragon Fund (backed by TigerMed) have invested $45 million to support the new venture, as well as Cytovia research and development projects.
WebCytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline. Shanghai, Shanghai, China 11-50 Undisclosed Private www.cytoviatx.com/cytolynx-therapeutics 52,817 Highlights Total Funding Amount $45M Contacts 11 Employee Profiles 1 Investors 5 Similar Companies 7 Funding Round • Sep …
WebOct 25, 2012 · Dr. Jocelyn Patricia Serrano - Ashburn VA, Family Practice at 44095 Pipeline Plz Suite 370. Phone: (703) 858-3140. View info, ratings, reviews, specialties, education … iontech axisWebJun 22, 2024 · Cytovia is uniquely positioned among NK cell companies with its broad technology capabilities across cell therapy, gene editing, and antibody therapeutics, as well as an exciting pipeline... on the grayscaleWebCytoLynx Therapeutics CEO Dr. Hong has over 25 years of combined medical and pharmaceutical industry experience, focusing on cancer immunotherapy across drug development and commercialization. Most recently, Dr. Hong served as the President of KLUS Pharma, Inc. based in the US, with a focus on its innovative pipeline and cell … ion tech center placervilleWebCytovia Therapeutics is a new biotech company formed in 2024 to build a portfolio of products to harness the power of NK cells in the treatment of … iontech cubaoWebApr 8, 2024 · Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the ... iontec brushWebApr 9, 2024 · Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. iontech engineering solutionsWebContact Email [email protected]. Phone Number 786-591-7001. Cytovia Therapeutics develops transformational cancer immunotherapies and addresses several unmet … ion tech gmbh